​

Kymera Therapeutics Ownership | Who Owns Kymera Therapeutics?

OverviewForecastRevenueFinancialsChartTranscripts

Kymera Therapeutics Ownership Summary

Kymera Therapeutics is owned by 97.92% institutional investors, 2.45% insiders. Price t rowe associates inc /md/ is the largest institutional shareholder, holding 9.03% of KYMR shares. US Small-Cap Growth II Equity Comp is the top mutual fund, with 4.14% of its assets in Kymera Therapeutics shares.

KYMR Ownership Benchmark

TypeName% Inst% Insiders% Retail
StockKymera Therapeutics97.92%2.45%-0.37%
SectorHealthcare Stocks 488.17%11.08%-399.26%
IndustryBiotech Stocks 306.59%11.10%-217.69%

Institutional Shareholders

Top Institutional Shareholders by Total Shares

HolderShares% HoldingValue
Price t rowe associates inc /md/6.87M9.03%$276.39M
Baker bros. advisors lp6.65M8.27%$290.27M
Avoro capital advisors6.56M8.15%$286.08M
Wellington management group llp5.31M6.97%$213.51M
Bvf inc/il5.50M6.84%$240.14M
Vanguard group4.89M6.42%$196.62M
Fmr4.83M6.35%$194.33M
Atlas venture life science advisors4.90M6.09%$213.68M
Blackrock4.16M5.87%$124.04M
Blackrock funding, inc. /de4.15M5.16%$181.03M

Top Institutional Shareholders by % of Total Assets

HolderShares% AssetsValue
Atlas venture life science advisors4.90M32.26%$213.68M
Aju ib investment457.06K21.71%$19.95M
Merck772.16K15.63%$33.70M
Bvf inc/il5.50M8.58%$240.14M
Siren3.43M7.74%$149.60M
Aquilo capital management138.52K6.80%$3.79M
Avoro capital advisors6.56M5.01%$286.08M
Redmile group803.29K3.73%$35.06M
Foresite capital management vi146.33K3.59%$6.39M
Baker bros. advisors lp6.65M2.82%$290.27M

Top Buyers

HolderShares% AssetsChange
Capital research global investors1.26M0.01%896.99K
Wellington management group llp5.31M0.04%688.97K
Baker bros. advisors lp6.65M2.82%655.50K
Blackrock4.16M0.00%499.77K
Millennium management510.48K0.01%394.56K

Top Sellers

HolderShares% AssetsChange
Deep track capital, lp---600.33K
Avidity partners management lp---500.00K
First light asset management---383.31K
Ecor1 capital---350.00K
Rock springs capital management lp450.37K1.22%-344.06K

New Positions

HolderShares% AssetsChangeValue
Adage capital partners gp304.20K0.02%304.20K$13.28M
Suvretta capital management275.00K0.36%275.00K$12.00M
Polar capital250.00K0.06%250.00K$10.91M
Perceptive advisors210.11K0.34%210.11K$9.17M
Point72 asset management184.48K0.02%184.48K$8.05M

Sold Out

HolderChange
Global financial private client-1.00
Financial gravity asset management-2.00
Capital performance advisors llp-3.00
True wealth design-6.00
Riggs asset managment-7.00

Institutional Ownership Trends

DateHoldingsChange %SharesChange %OwnershipChange %Increased PositionChange %Decreased PositionChange %
Jun 30, 202521518.78%78,776,9568.20%971.19%13248.31%52-7.14%
Mar 31, 202520-89.07%22,191,205-69.06%270.31%7-92.39%4-93.10%
Dec 31, 2024180-0.55%71,156,6423.18%931.14%88-4.35%59-4.84%
Sep 30, 202418116.03%68,964,5512.37%901.00%936.90%6231.91%
Jun 30, 2024155-4.32%67,367,8330.44%950.72%86-14.85%4711.90%

Top Mutual Funds Shareholders

HolderShares% HoldingChange
US Small-Cap Growth II Equity Comp2.90M4.14%-150.42K
T. Rowe Price New Horizons2.90M4.14%131.16K
Fidelity Growth Compy Commingled Pl O2.24M3.46%52.60K
Vanguard Health Care Inv2.39M3.40%-626.58K
Fidelity Growth Compy Commingled Pl S2.34M3.34%230.06K
Vanguard Total Stock Mkt Idx Inv1.88M2.66%-39.75K
Vanguard US Total Market Shares ETF1.54M2.38%1.91K
Fidelity Growth Company Fund1.64M2.34%170.30K
Vanguard Small Cap Index1.45M2.05%-9.73K
T. Rowe Price Health Sciences1.37M1.95%190.87K

Recent Insider Transactions

DateNameRoleActivityValue
Jun 30, 2025BVF PARTNERS L P/IL See Remarks and FootnotesBuy$2.59M
Jun 30, 2025BVF PARTNERS L P/IL See Remarks and FootnotesBuy$5.09M
Jun 30, 2025BVF PARTNERS L P/IL See Remarks and FootnotesBuy$6.27M
Jun 30, 2025BAKER BROS. ADVISORS LP-Buy$26.41M
Jun 30, 2025BAKER BROS. ADVISORS LP-Buy$5.52

Insider Transactions Trends

DateBuySell
2025 Q3--
2025 Q277
2025 Q1-9
2024 Q4-1
2024 Q3516

KYMR Ownership FAQ

Who Owns Kymera Therapeutics?

Kymera Therapeutics shareholders are primarily institutional investors at 97.92%, followed by 2.45% insiders and -0.37% retail investors. The average institutional ownership in Kymera Therapeutics's industry, Biotech Stocks , is 306.59%, which Kymera Therapeutics falls below.

Who owns the most shares of Kymera Therapeutics?

Kymera Therapeutics’s largest shareholders are Price t rowe associates inc /md/ (6.87M shares, 9.03%), Baker bros. advisors lp (6.65M shares, 8.27%), and Avoro capital advisors (6.56M shares, 8.15%). Together, they hold 25.44% of Kymera Therapeutics’s total shares outstanding.

Does Blackrock own Kymera Therapeutics?

Yes, BlackRock owns 5.87% of Kymera Therapeutics, totaling 4.16M shares as of Jun 2024. This represents 0.00% of BlackRock's total assets, with a market value of 124.04M$. In the last quarter, BlackRock increased its holdings by 499.77K shares, a 13.67% change.

Who is Kymera Therapeutics’s biggest shareholder by percentage of total assets invested?

Atlas venture life science advisors is Kymera Therapeutics’s biggest shareholder by percentage of total assets invested, with 32.26% of its assets in 4.9M Kymera Therapeutics shares, valued at 213.68M$.

Who is the top mutual fund holder of Kymera Therapeutics shares?

US Small-Cap Growth II Equity Comp is the top mutual fund holder of Kymera Therapeutics shares, with 4.14% of its total shares outstanding invested in 2.9M Kymera Therapeutics shares.

Try Tickergate Pro Free

Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)

  • Customize your own personal stocks lists, views and charts

  • Choose from hundreds of fields, up to 15 years of history

  • Conduct deep comparison analysis

  • Discover trending investment themes

  • Find your next best investment

  • Research stocks using tools